Insider Transactions in Q1 2024 at Alpine Immune Sciences, Inc. (ALPN)
Insider Transaction List (Q1 2024)
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Jan 26
2024
|
James Paul Rickey Officer |
SELL
Open market or private sale
|
Direct |
117,764
-100.0%
|
$2,708,572
$23.66 P/Share
|
|
Jan 26
2024
|
James Paul Rickey Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
117,764
+50.0%
|
$942,112
$8.91 P/Share
|
|
Jan 25
2024
|
James Paul Rickey Officer |
SELL
Open market or private sale
|
Direct |
236
-100.0%
|
$5,192
$22.0 P/Share
|
|
Jan 25
2024
|
James Paul Rickey Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
236
+50.0%
|
$1,416
$6.51 P/Share
|
|
Jan 18
2024
|
Decheng Capital China Life Sciences Usd Fund Iii, L.P. > 10% Shareholder |
BUY
Exercise of in-the-money or at-the-money derivatives securities
|
Direct |
1,234,636
+15.79%
|
$14,815,632
$12.74 P/Share
|
|
Jan 18
2024
|
Xiangmin Cui Director |
BUY
Exercise of in-the-money or at-the-money derivatives securities
|
Indirect |
1,234,636
+15.79%
|
$14,815,632
$12.74 P/Share
|
|
Jan 11
2024
|
Peter A. Thompson Director |
BUY
Exercise of in-the-money or at-the-money derivatives securities
|
Indirect |
145,251
+5.67%
|
$1,743,012
$12.74 P/Share
|
|
Jan 11
2024
|
Orbimed Advisors LLC Director |
BUY
Exercise of in-the-money or at-the-money derivatives securities
|
Indirect |
145,251
+5.67%
|
$1,743,012
$12.74 P/Share
|
|
Jan 04
2024
|
Remy Durand Chief Business Officer |
BUY
Grant, award, or other acquisition
|
Direct |
31,200
+45.02%
|
-
|
|
Jan 04
2024
|
James Paul Rickey Officer |
BUY
Grant, award, or other acquisition
|
Direct |
31,200
+50.0%
|
-
|
|
Jan 04
2024
|
Stanford L Peng Officer |
BUY
Grant, award, or other acquisition
|
Direct |
48,000
+39.88%
|
-
|
|
Jan 04
2024
|
Mitchell Gold Executive Chairman and CEO |
BUY
Grant, award, or other acquisition
|
Direct |
96,000
+50.0%
|
-
|